Abcuro Closes $200M Series C to Advance First-In-Class IBM Therapy Ulviprubart Toward Approval and Commercialization

Newton, MA, February 12, 2025 (Business Wire) -- Abcuro, Inc. has secured $200 million in Series C financing, led by New Enterprise Associates (NEA) with participation from new and existing investors, to advance its first-in-class therapy, ulviprubart, for inclusion body myositis (IBM). The funding will support the completion of the registrational Phase 2/3 MUSCLE trial, preparation for a Biologics License Application (BLA) filing, and commercial launch readiness. With ulviprubart targeting a significant unmet clinical need, Abcuro is poised to reshape the treatment landscape for IBM through precise modulation of cytotoxic T cells.

Read full article here.